Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids

Clinical and Experimental Rheumatology

Volumn 27, Issue 4, 2009, Pages 567-573

  Benucci, M ^a   Saviola, Gianantonio ^b   Baiardi, P ^c   Abdi Ali, L ^b   Povino, M R ^b   Dolenti, S ^d   Campostrini, L ^b   Sacco, S ^b   Manfredi, M ^a   Rossini, M ^e  

^a Osp S Giovanni Di Dio   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

Bisphophonates; Bone markers; Glucocorticoid induced osteoporosis; Neridronate; Rheumatic diseases

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; DEOXYPYRIDINOLINE; METHYLPREDNISOLONE; NERIDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; VITAMIN D;

ACUTE PHASE RESPONSE; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG CONTRAINDICATION; DRUG FEVER; DRUG INDUCED HEADACHE; ESOPHAGUS DISEASE; FEMALE; FEMUR NECK; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OSTEOPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; SIDE EFFECT; STOMACH DISEASE; STOMACH PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; DRUG THERAPY, COMBINATION; FEMALE; FEMUR; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAMUSCULAR; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; RHEUMATIC DISEASES; YOUNG ADULT;

EID: 70350163841     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. VAN STAA TP, LEUFKENS HG, ABENHAIM L et al.: Oral corticosteroid and fracture risk: relationship to daily and cumulative dose. Rheumatology 2000; 39: 1383-1389
2. IWAMOTO J, TAKEDA T, SATO Y: Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced-osteoporosis-usefulness of alendronate and risedronate. Expert Opin Pharmacother 2007; 8: 2743-2756
3. BERRIS KK, REPP AL, KLEEREKOPER M: Glucocorticoid induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 2007; 14: 446-450
4. DE GROEN PC, LUBBE DF, HIRSCH U et al.: Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021
5. FERNANDES PA, PIRAS MS, GOUVEA AP: Ulcerative esophagitis associated with the use of alendronate sodium: histopathological and endoscopic features. Arq Gastroenterol 2002; 39: 173-176
6. CURTIS JR, SAAG KG: Prevention and treatment of glucocorticoid induced osteoporosis. Curr Osteoporos Rep 2007; 5: 14-21.
7. RINGE JD, DORST A, FABER A et al.: Three monthly bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid induced osteoporosis. Rheumatology 2003; 42: 743-749
8. CURTIS JR, WESTFALL AO, ALLISON JJ et al.: Channelling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006; 17: 1268-1274
9. DOWNEY TW, FOLTZ SH, BOCCUZZI SJ, OMAR MA, KAHLER KH: Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006; 99: 570-575
10. CRAMER JA, AMONKAR MM, HEBBORN A et al.: Compliance and persistence with bisphosphonates dosing regimen among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460 (Pubitemid 41368578)
11. GOLD DT, SAFI W, TRINH H: Patients preference and adherence: comparative US studies between two bisphosphonates, weekly rise-dronate and monthly ibandronate. Curr Med Res Opin 2006; 22: 2383-2391
12. BRANKIN E, WALKER M, LYNCH N et al.: The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006; 22: 1249-1256
13. CIVITELLI R, NAPOLI N, ARMAMENTO-VILLAREAL R: Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 2007; 5: 8-13.
14. GATTI D, VIAPIANA O, LIPPOLIS I et al.: Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. J Bone Miner Res 2005; 20: 1323-1326
15. GATTI D, ANTONIAZZI F, PRIZZI R et al.: Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-763
16. ADAMI S, BEVILACQUA M, BROGGINI M et al.: Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol 2002; 20: 55-58 (Pubitemid 34213733)
17. MERLOTTI D, GENNARI L, MARTINI G et al.: Comparison of different intravenous bisphosphonate regimen for Paget's disease of bone. J Bone Miner Res 2007; 22: 1510-1517 (Pubitemid 351229321)
18. D'EUFEMIA P, FINOCCHIARO R, CELLI M et al.: High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment. Pediatr Res 2008; 63: 203-206
19. BRAGA V, GATTI D, COLAPIETRO F et al. Intravenous intermittent neridronate in the treatment of postmenopausal osteoporosis. Bone 2003; 33: 342-345 (Pubitemid 37114940)
20. CASCELLA T, MUSELLA T, ORIO F JR et al.: Effects of neridronate treatment in elderly women with osteoporosis. J Endocrinol Invest 2005; 28: 202-208 (Pubitemid 43162765)
21. ADAMI S, BRAGA V, LO CASCIO et al.: A multicenter double-blind between patient, placebo controlled study to assess the efficacy and tolerability of different treatment regimens of neridronate ampoules administered by intramuscular route to women affected by postmenopausal osteoporosis (studio NEOP-01) Clinical Cases in Mineral Bone Metabolism 2006; 3: 233-234
22. ADAMI S, GATTI D, BERTOLDO F et al.: Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int 2008; 83: 301-307.
23. SAVIOLA G, ABDI ALI L, SHAMS EDDIN S et al.: Can neridronate be effective in the treatment of osteoporosis in hypogonadic men? Clin Exp Rheumatol 2007; 25: 340.
24. LA MONTAGNA G, MALESCI D, TIRRI R et al.: Successful neridronate therapy in transient osteoporosis of the hip. Clin Rheumatol 2005; 24: 67-69
25. CORRADO A, QUARTA L, ERRICO S et al.: Successful treatment of avascular bone necrosis of the knee with neridronate: a case report. Rheumatol Int 2007; 27: 891-893 (Pubitemid 46906640)
26. PITTARI G, COSTI D, RABALLO M et al.: Intravenous neridronate for skeletal damage treatment in patients with multiple myeloma. Acta Biomed 2006; 77: 81-84
27. BENUCCI M, DOLENTI S, SAVIOLA G et al.: Modifications of markers of bone resorption in patients affected by Glucocorticoid Induced Osteoporosis (GIO) treated with Neridronate. Recenti Prog Med 2006; 97: 24-27
28. VAN STAA TP, GEUSENS P, POLS HA et al.: A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM, 2005; 98: 191-198
29. CANALIS E, BILEZIKIAN JP, ANGELI A et al.: Perspectives on glucocorticoid induced osteoporosis. Bone 2006; 34: 593-598
30. AMERICAN COLLEGE OF RHEUMATOLOGY AD HOC COMMITTEE ON GLUCOCORTICOID- INDUCED OSTEOPOROSIS: Reccommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001; 44: 1496-1503
31. YAMADA S, TAKAGI H, TSUCHIYA H et al.: Comparative studies of risedronate and alfacalcidiol against glucocorticoid induced osteoporosis in rheumatoid arthritic patients. Yakugaru Zasshi 2007; 127: 1491-1496
32. LEMS WF, LODDER MC, LIPS P et al.: Positive effects of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone; a randomized, double-blind, placebo controlled trial. Osteoporos Int 2006 17: 716-723
33. TASCIOGLU F, COLK O, ARMAGAN O et al.: The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. Rheumatol Int 2005 26: 21-29
34. GOUGH A, SAMBROOK P, DEVLIN J et al.: Osteoclastic attivation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: 1282-1289
35. GANESAN K, TEKLEHAIMANOT S, TRAN TH et al.: Relationship of C-reactive protein and bone mineral density in community-dwelling elder females. J Natl Med Assoc 2005; 97: 329-333 (Pubitemid 40315936)
36. LANE N E, GOLDRING SR: Bone loss in rheumatoid arthritis: what role does inflammation play? J Rheumatol 1998; 25: 1251-1253
37. FREDIANI B, SPREAFICO A, CAPPERUCCI C et al.: Long-term effects of neridronate on human osteoblastic cell cultures. Bone 2004; 35: 859-869
38. SPREAFICO A, FREDIANI B, CAPPERUCCI C et al.: Anabolic effects and inhibition of interleukin 6 production by neridronate on human osteoblasts. Reumatismo 2006; 58: 288-300.
39. CORRADO A, CANTATORE FP, GRANO M et al.: Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol 2005; 24: 527-534
40. JACOBS JWG, DE NIJS RNJ, LEMS WF et al.: Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidiol: relations of change in bone mineral density, bone markers and calcium Homeostasis. J Rheumatol 2007; 34: 1051-1057
41. SHENKER NG, JAWAD ASM: Bisphosphonates and osteonecrosis of the jaw. Rheumatology 2007, 46: 1049-1051